Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study.
Muñoz-Martínez S, Sapena V, Forner A, Bruix J, Sanduzzi-Zamparelli M, Ríos J, Bouattour M, El-Kassas M, Leal CRG, Mocan T, Nault JC, Alves RCP, Reeves HL, da Fonseca L, García-Juárez I, Pinato DJ, Varela M, Alqahtani SA, Alvares-da-Silva MR, Bandi JC, Rimassa L, Lozano M, González Santiago JM, Tacke F, Sala M, Anders M, Lachenmayer A, Piñero F, França A, Guarino M, Elvevi A, Cabibbo G, Peck-Radosavljevic M, Rojas Á, Vergara M, Braconi C, Pascual S, Perelló C, Mello V, Rodríguez-Lope C, Acevedo J, Villani R, Hollande C, Vilgrain V, Tawheed A, Ferguson Theodoro C, Sparchez Z, Blaise L, Viera-Alves DE, Watson R, Carrilho FJ, Moctezuma-Velázquez C, D'Alessio A, Iavarone M, Reig M.
Muñoz-Martínez S, et al.
Liver Int. 2022 Aug;42(8):1891-1901. doi: 10.1111/liv.15320. Epub 2022 Jun 23.
Liver Int. 2022.
PMID: 35608939
Free PMC article.
The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24-12.74], 11.76% [95% CI 4.73-22.30], 20.69% [95% CI 11.35-31.96] and 34.52% [95% CI 17.03-52.78] for BCLC 0/A, B, C and D, respectively; p = .0017). The hazard ratio was 1.45 …
The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24-12.74], 11.76% [95% CI 4.73-22.30], 20.6 …